MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.


Study fully funded by BARDA

YAVNE, Israel, June 19, 2018 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to United States burn centers, following approval of the study protocol by the U.S. Food and Drug Administration (FDA) and site Institutional Review Boards (IRB).
“We are very pleased to initiate enrollment of our CIDS Phase 3 study in the U.S., providing the opportunity to U.S. burn experts to treat pediatric patients with NexoBrid,” said Gal Cohen, President and Chief Executive Officer of MediWound. “The current management of pediatric burns requires intensive medical therapy and typically several traumatic surgical procedures to remove eschar and prevent secondary complications. Burn surgery in pediatric patients is very demanding for a variety of reasons, such as complex anesthesia, thinner skin leaving narrow safety margins for surgical intervention, less skin graft donor site area and difficulties to diagnose burn severity early in scalding burns that are frequent in children. Published clinical results to date have demonstrated the merits of using NexoBrid as a non-surgical means to manage and treat these young patients including earlier eschar removal, reduced incidence and extent of surgical excision, grafting and blood loss. Our team is highly motivated to bring NexoBrid treatment to these young, vulnerable patients and this study expansion bring us one step closer to that goal,” added Mr. Cohen.

For more information please visit



Share this Page: